Review Article

Liver Fibrosis and Cardiovascular Events

Authors: Nso Nso, MD, MPH, Kaveh Rezaei Bookani, MD, Mia Trimingham, , Richard Orji, MD, Basile Njei, MD, MPH, PhD, Senthil S. Balasubramanian, MD, MSCI, Amit Pursnani, MD

Abstract

Objectives: Liver fibrosis represents a common sequela of nonalcoholic fatty liver disease (NAFLD) and other chronic liver diseases. Noninvasive liver fibrosis scores (LFSs) aim to evaluate the severity of liver fibrosis. Whether LFSs can predict the risk of future cardiovascular events (CVEs) remains unclear. This systematic review aimed to clarify the association between liver fibrosis and CVEs by studying the value of LFSs, namely the Fibrosis-4 (FIB-4) Index for Liver Fibrosis score and the NAFLD Fibrosis Score (NFS), for predicting CVEs.

Methods: PubMed, Scopus, Web of Science, and Cochrane Library were searched for relevant prospective studies. Retrieved articles were screened to confirm their eligibility for the systematic review. We evaluated the quality of the included studies using the National Institutes of Health tool.

Results: Twelve studies of high to fair quality were included in this systematic review. Of note, 10/12 studies reported an independent association between high LFSs and the risk of CVEs, cardiovascular mortality, and all-cause mortality (all P < 0.05). In addition, an advanced histological grade of liver fibrosis (grade 3 or 4) was suggestive of CVE occurrence. NAFLD also appeared to be associated with a higher risk of CVEs at any severity of fibrosis (all P < 0.05).

Conclusions: The findings of this review suggest that liver fibrosis in patients with NAFLD is an independent predictor of future adverse CVEs, cardiovascular mortality, and all-cause mortality. Noninvasive and easy-to-perform LFSs, including FIB-4 score and the NFS, appear useful in predicting such events in patients with a spectrum of cardiovascular diseases and the general population without known cardiovascular disease.
Posted in: Liver Disease9

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Browning JD, Szczepaniak LS, Dobbins R, et al, Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387–95.
 
2. Dulai PS, Singh S, Patel J, et al, Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 2017;65:1557–1565.
 
3. Ekstedt M, Hagström H, Nasr P, et al, Fibrosis stage is the strongest predictor for diseasespecific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61: 1547–1554.
 
4. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495–500.
 
5. Saadeh S, Cammell G, Carey WD, et al. The role of liver biopsy in chronic hepatitis C. Hepatology 2001;33:196–200.
 
6. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341–1350.
 
7. Angulo P, Hui JM, Marchesini G, et al, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846–854.
 
8. McPherson S, Stewart SF, Henderson E, et al, Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010;59:1265–1269.
 
9. Shah AG, Lydecker A, Murray K, et al, Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7:1104–1112.
 
10. Siddiqui MS, Yamada G, Vuppalanchi R, et al. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin Gastroenterol Hepatol 2019;17:1877–1885.e5.
 
11. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. JHepatol2015;63:237–264.
 
12. Bedossa P, Patel K. Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease. Gastroenterology 2016;150:1811–1822.e4.
 
13. Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol 2018;68:305–315.
 
14. Kim D, Kim WR, Kim HJ, et al, Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013;57:1357–1365.
 
15. Unalp-Arida A, Ruhl CE. Liver fibrosis scores predict liver disease mortality in the United States population. Hepatology 2017;66:84–95.
 
16. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43: 1317–1325.
 
17. SumidaY, Yoneda M, Hyogo H,et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol 2012;12:2.
 
18. Jaruvongvanich V, Wijarnpreecha K, Ungprasert P. The utility of NAFLD fibrosis score for prediction of mortality among patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of cohort study. Clin Res Hepatol Gastroenterol 2017;41:629–634.
 
19. Takahashi T, Watanabe T, Shishido T, et al. The impact of non-alcoholic fatty liver disease fibrosis score on cardiac prognosis in patients with chronic heart failure. Heart Vessels 2018; 33:733–739.
 
20. Abeles RD, Mullish BH, Forlano R, et al. Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume. Aliment Pharmacol Ther 2019;49: 1077–1085.
 
21. Baratta F, Pastori D, Angelico F, et al. Nonalcoholic fatty liver disease and fibrosis associated with increasedriskofcardiovascular eventsina prospective study. ClinGastroenterol Hepatol 2020;18:2324–2331.e4.
 
22. SumidaY,YonedaM,TokushigeK,etal.FIB-4first in the diagnostic algorithm of metabolic dysfunction-associated fatty liver disease in the era of the global metabodemic. Life (Basel) 2021;11:143.
 
23. Patil R, Sood GK. Non-alcoholic fatty liver disease and cardiovascular risk. World J Gastrointest Pathophysiol 2017;8:51–58.
 
24. Patel K, Wilder J. Fibroscan. Clin Liver Dis 2014;4:97–101.
 
25. Del Ben M, Baratta F, Polimeni L, et al. Under-prescription of statins in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2017;27:161–167.
 
26. Targher G, Byrne CD, Lonardo A, et al, Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. JHepatol2016;65:589–600.
 
27. Salomone F, Micek A, Godos J. Simple scores of fibrosis and mortality in patients with NAFLD: a systematic review with meta-analysis. JClinMed2018;7:219.
 
28. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
 
29. MaL-L, WangY-Y, YangZ-H, et al. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res2020; 7:7.
 
30. Henson JB, Simon TG, Kaplan A, et al. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2020;51:728–736.
 
31. Cao YX, Zhang M, Zhang HW, et al. Impact of liver fibrosis score on prognosis in patients with previous myocardial infarction: a prospective cohort study. Liver Int 2021;41: 1294–1304.
 
32. Jin JL, Zhang HW, Cao YX, et al. Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease. Hepatol Int 2021;15:413–423.
 
33. Takae M, Fujisue K, Yamamoto E, et al, Prognostic significance of liver stiffness assessed by fibrosis-4 index in patients with heart failure. ESC Heart Fail 2021;8:3809–3821.
 
34. Nakashima M, Sakurag S, Miyoshi T, et al. Fibrosis-4 index reflects right ventricular function and prognosis in heart failure with preserved ejection fraction. ESC Heart Fail 2021;8: 2240–2247.
 
35. So-Armah KA, Lim JK, Lo Re V, et al. FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients. Hepatology 2017;66:1286–1295.
 
36. Liu HH, Cao YX, Jin JL, et al. Liver fibrosis scoring systems as novel tools for predicting cardiovascular outcomes in patients following elective percutaneous coronary intervention. J Am Heart Assoc 2021;10:e018869.
 
37. Peters AE, Pandey A, Ayers C, et al. Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT. ESC Heart Fail 2021;8:842–848.
 
38. Hagstrom H, Nasr P, Ekstedt M, et al. Cardiovascular risk factors in non-alcoholic fatty liver disease. Liver Int 2019;39:197–204.
 
39. Yoshihisa A, Sato Y, Yokokawa T, et al. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction. ESC Heart Fail 2018;5:262–270.
 
40. Patidar Y, Singh J, Chatterjee N, et al. Real-time shear wave elastography for determining the ideal site of liver biopsy in diffuse liver disease. Indian J Radiol Imag 2023;34:44–53.
 
41. Sande JA, Verjee S, Vinayak S, et al. Ultrasound shear wave elastography and liver fibrosis: a prospective multicenter study. World J Hepatol 2017;9:38–47.